Patent classifications
C12N15/09
Encryption method, decryption method, encryption system and decryption system
An encryption method includes an operation method of an encryption system and is a method of encrypting encryption target information.
Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector
The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.
Fusion protein or conjugated protein, intracellular delivery carrier, partial peptide, cell membrane permeation enhancer, DNA, and vector
The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.
Nitrogen responsive transcription factors in plants
Methods for increasing or decreasing Nitrogen (N) uptake/assimilation and/or usage in plants comprising over-expressing or repressing one or more transcription factors that have been identified by evaluating temoporal transcription of the TFs in response to N signaling and validated based on TF perturbation studies in plant cells and plants. Combinations of TFs may be used, where each TF may be independently induced or repressed to achieve a desired increase or decrease in N uptake/assimilation.
Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
Disclosed herein is a functional nucleic acid that includes i) one or more coding nucleotide sequences encoding a genome editing endonuclease; ii) regulatory sequences operably linked to the one or more coding nucleotide sequences; and iii) one or more genome editing endonuclease-recognized sequences, wherein the functional nucleic acid is configured to express the endonuclease in a host cell and thereby provide a cellular endonuclease activity in a sequence-specific manner in the host cell, and wherein cleavage of the functional nucleic acid by the endonuclease inactivates the cellular endonuclease activity. Methods of using the present functional nucleic acid, and systems and kits that find use in performing the same are also provided.
Hemicellulase compositions
Hemicellulase that degrades corn non-starch polysaccharides (“NSP”), DNA encoding the same, and a method of using the hemicellulase and its DNA are provided. Proteins having hemicellulase activity such as Xyn5A, Xyn10B, Xyn11A, Xyn30A, and Xyn43A are described.
Hemicellulase compositions
Hemicellulase that degrades corn non-starch polysaccharides (“NSP”), DNA encoding the same, and a method of using the hemicellulase and its DNA are provided. Proteins having hemicellulase activity such as Xyn5A, Xyn10B, Xyn11A, Xyn30A, and Xyn43A are described.
Reaction processor
A reaction processor includes: a reaction processing vessel including a channel in which a sample moves and a pair of air communication ports, a first air communication port and a second air communication port, provided at respective ends of the channel; a temperature control system that provides a medium temperature region and a high temperature region between the first air communication port and the second air communication port in the channel; and a liquid feeding system that discharges and sucks air in order to move and stop the sample inside the channel. One of the pair of air communication ports of the reaction processing vessel that is farther away from the high temperature region communicates with the liquid feeding system via a tube. One of the pair of air communication ports of the reaction processing vessel that is closer to the high temperature region is opened to atmospheric pressure.
METHOD FOR DETERMINING PRESENCE OR ABSENCE OF RISK OF DEVELOPING CANCER
An object of the present invention is to provide a method for predicting a risk of developing cancer. DNA samples were prepared from blood and cancer tissues of 2480 cancer patients and analyzed for the nucleotide sequences of exon regions using NGS. As a result, among the cancer patients, 7 patients were confirmed to have D49H mutation or A159D mutation which is a germ cell mutation.
Method for preparing genetically-modified T cells which express chimeric antigen receptor
In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.